Evidence map›Paper›PMID 32107846›Full record

ArticleMolecular oncology2020

Bispecific human IL2-CCR4 immunotoxin targets human cutaneous T-cell lymphoma.

Haoyu Wang, Zhaohui Wang, Huiping Zhang, Zeng Qi, Ariel C Johnson, David Mathes, Elizabeth A Pomfret, Erin Rubin, Christene A Huang, Zhirui Wang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. "Next top" mouse models advancing CTCL research.Frontiers in cell and developmental biology · 2024
    Review
  7. Review
  8. Article
  9. Novel targeted therapies of T cell lymphomas.Journal of hematology & oncology · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Haoyu WangDivision of Plastic and Reconstructive Surgery, Department of Surgery, School of Medicine, University of Colorado Denver, Aurora, CO, USA.
Zhaohui WangDivision of Plastic and Reconstructive Surgery, Department of Surgery, School of Medicine, University of Colorado Denver, Aurora, CO, USA.
Huiping ZhangDivision of Plastic and Reconstructive Surgery, Department of Surgery, School of Medicine, University of Colorado Denver, Aurora, CO, USA.
Zeng QiDivision of Plastic and Reconstructive Surgery, Department of Surgery, School of Medicine, University of Colorado Denver, Aurora, CO, USA.ORCID 0000-0002-3553-0349
Ariel C JohnsonDivision of Plastic and Reconstructive Surgery, Department of Surgery, School of Medicine, University of Colorado Denver, Aurora, CO, USA.
David MathesDivision of Plastic and Reconstructive Surgery, Department of Surgery, School of Medicine, University of Colorado Denver, Aurora, CO, USA.
Elizabeth A PomfretDivision of Transplant Surgery, Department of Surgery, School of Medicine, University of Colorado Denver, Aurora, CO, USA.
Erin RubinTransplantation Pathology, Department of Pathology, School of Medicine, University of Colorado Denver, Aurora, CO, USA.
Christene A HuangDivision of Plastic and Reconstructive Surgery, Department of Surgery, School of Medicine, University of Colorado Denver, Aurora, CO, USA.
Zhirui WangDivision of Plastic and Reconstructive Surgery, Department of Surgery, School of Medicine, University of Colorado Denver, Aurora, CO, USA.ORCID 0000-0002-0046-2294
Harvard University · USUniversity of Colorado Denver · USShanxi Agricultural University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The majority of clinically diagnosed cutaneous T-cell lymphomas (CTCL) highly express the cell-surface markers CC chemokine receptor 4 (CCR4) and/or CD25. Recently, we have developed diphtheria toxin-based recombinant Ontak®-like human IL2 fusion toxin (IL2 fusion toxin) and anti-human CCR4 immunotoxin (CCR4 IT). In this study, we first compared the efficacy of the CCR4 IT vs IL2 fusion toxin for targeting human CD25

Indexed as

AnimalsDiphtheria ToxinFlow CytometryHumansImmunotoxinsInhibitory Concentration 50Interleukin-2Interleukin-2 Receptor alpha SubunitLymphoma, T-Cell, CutaneousMiceReceptors, CCR4Recombinant Fusion ProteinsRecombinant ProteinsSkin NeoplasmsXenograft Model Antitumor AssaysCCR4 protein, humandenileukin diftitoxDiphtheria ToxinIL2 protein, humanIL2RA protein, humanImmunotoxinsInterleukin-2Interleukin-2 Receptor alpha SubunitReceptors, CCR4Recombinant Fusion ProteinsRecombinant ProteinsCCR4cutaneous T-cell lymphomaIL2immunotoxinOntak®

Identifiers

PMID32107846
PMCPMC7191189
OpenAlexW3007758317

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.